Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | MMP9 | P14780 | 2/20 | 0.31 |
| ▸ | MMP8 | P22894 | 2/20 | 0.31 |
| ▸ | MMP13 | P45452 | 2/20 | 0.31 |
| ▸ | MAOB | P27338 | 2/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL605319 | 0.64 | MAOA (0.34) | ELANECYP3A4MAOBMAOAMEN1 | |
| SCHEMBL2280698 | 0.62 | MAOA (0.39) | CYP3A4MMP2MMP9MMP8MMP13 | |
| SCHEMBL29195204 | 0.59 | ELANE (0.46) | ELANECYP3A4MMP2MMP9MMP8 | |
| SCHEMBL13886739 | 0.57 | TLR9 (0.46) | ELANEBACE1MMP2MMP9MMP8 | |
| SCHEMBL16865428 | 0.57 | MMP9 (0.56) | ELANECYP3A4MMP2MMP9MMP8 | |
| SCHEMBL29256181 | 0.56 | ELANE (0.56) | ELANEBACE1MMP2MMP9MMP8 | |
| SCHEMBL31206797 | 0.56 | ALDH1A1 (0.35) | ELANECYP3A4MAOBMAOACA2 | |
| SCHEMBL12326483 | 0.55 | — | — | |
| SCHEMBL12418929 | 0.55 | — | — | |
| SCHEMBL11256566 | 0.55 | ELANE (0.42) | ELANECYP3A4MMP2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018382-B2 | Indazoles | GLAXOSMITHKLINE LLC (US) | 2015-04-28 | — | — | US | disclosed |
| EP-2566328-B1 | INDAZOLES | GLAXOSMITHKLINE LLC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20140350013-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2014-11-27 | — | — | US | disclosed |
| US-8846935-B2 | Indazoles | GLAXOSMITHKLINE LLC (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2566328-A1 | INDAZOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20130053383-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| WO-2011140325-A1 | INDAZOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053383-A1 | INDAZOLES | IDH3A, CYP3A7, IDH3B | ELANE 1385/4885DDB1 946/4885CRBN 2225/4885 |
| US-20140350013-A1 | INDAZOLES | IDH3A, CYP3A7, IDH3B | ELANE 1385/4885DDB1 946/4885CRBN 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.